Solid Double-Digit Profits Growth For Novo Nordisk In 1996

17 March 1997

Danish company Novo Nordisk had a good year in 1996, with pretax profitsrising 17% to 2.52 billion Danish kroner ($388.2 million). Net income was 1.80 billion kroner, up 15%, and operating profits were 2.39 billion kroner, also up 15%.

For the year, consolidated sales were up 8% to 14.87 billion kroner. Revenues for continuing businesses were up 12% in kroner, and 13% in local currencies.

The firm's health care business achieved turnover of 11.1 billion kroner, up 12%. The unit felt a 2% negative impact from currencies, with volume and product mix positively affecting sales by 14%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight